Nanolattix Chairwoman Dr. Zhuican Qu Makes Appearance at the 25th Annual Biotech in Europe Forum
Release time:
2025-10-11
The 25th Annual Biotech in Europe Forum was held in Basel, Switzerland from October 8th to 9th, 2025. Dr. Zhuican Qu, Chairwoman of Nanolattix, and Ms. Elizabeth Wu, Head of International Business, were invited to attend this prestigious global biotechnology event.
On October 8th, Dr. Qu delivered a keynote speech, outlining Nanolattix's cutting-edge strategy and R&D capabilities in the field of oncology. She highlighted the company's core investigational drug T320, which targets various malignant solid tumors such as cervical cancer and pancreatic cancer. The clinical trial commenced at the beginning of this year and has enrolled patients across five clinical centers. Notably, stable disease (SD) has been observed as an early positive signal in some cervical cancer patients, garnering significant attention from attending experts.
Leveraging its proprietary BioLattix technology platform, Nanolattix has built a pipeline of next-generation anti-tumor drugs, including ADCs and RDCs. Among them, the first-in-class bispecific ADC drugs B836 and B830, as well as the RDC drug RT01, have all demonstrated promising therapeutic potential in preclinical studies, showcasing the company's diversified R&D strategies and technological expertise.
During the conference, Dr. Qu and Ms. Wu held multiple in-depth meetings with representatives from several renowned European pharmaceutical companies, research institutions, and life science investment firms. They conducted productive discussions on frontier trends in oncology, potential pathways for technological collaboration, and global market expansion. By actively engaging in diverse international exchanges, Nanolattix is committed to exploring new cooperation opportunities in the healthcare industry.
Tag:
recommend News
Share
